Biodegradable scleral plugs for vitreoretinal drug delivery.

Intraocular controlled drug release is one way to facilitate drug efficacy and decrease side effects that occur with systemic administration. Vitreoretinal drug delivery with the biodegradable scleral plug has been investigated. The scleral plug, which is made of biodegradable polymers and drugs, can be implanted at the pars plana using a simple procedure, and it gradually releases effective doses of drugs with polymer biodegradation for several months. The release profiles of the drugs were dependent on the kind of polymers used, their molecular weights, and the amount of drug in the plug. The plugs are effective for treating vitreoretinal diseases such as proliferative vitreoretinopathy. The implantation site was replaced with connective tissue. Electroretinography and histologic studies revealed little retinal toxicity. This implantable scleral plug was supposed to be advantageous for diseases such as cytomegalovirus retinitis that respond to repeated intravitreal injections and for vitreoretinal disorders that require vitrectomy.     

Biodegradable microspheres for parenteral delivery

Nowadays, emphasis is being laid to development of controlled release dosage forms. Interest in this technology has increased steadily over the past few years. Although oral administration of drugs is a widely accepted route of drug delivery, bioavailability of drug often varies as a result of gastrointestinal absorption, degradation by first-pass effect, and hostile environment of gastrointestinal tract. Transdermal administration for percutaneous absorption of drug is limited by the impermeable nature of the stratum corneum. Ocular and nasal delivery is also unfavorable because of degradation by enzymes present in eye tissues and nasal mucosa. Hence, the parenteral route is the most viable approach in such cases. Of the various ways of achieving long-term parenteral drug delivery, biodegradable microspheres are one of the better means of controlling the release of drug over a long time. Because of the lipidic nature of liposomes, problems such as limited physical stability and difficulty of freeze-drying are encountered. Similarly, for emulsions, stability on long-term basis and in suspensions, rheological changes during filling, injecting, and storage poses limitation. Also, in all these systems, the release rate cannot be tailored to the needs of the patient. Parenteral controlled-release formulations based on biodegradable microspheres can overcome these problems and can control the release of drug over a predetermined time span, usually in the order of days to weeks to months. Various FDA-approved controlled-release parenteral formulations based on these biodegradable microspheres are available on the market, including Lupron Depot Nutropin Depot and Zoladex. This review covers various molecules encapsulated in biodegradable microspheres for parenteral delivery.     

Biodegradable polymers for colon-specific drug delivery

This review focuses on the colonic drug delivery, especially using biodegradable polymers i.e. guar gum, chondroitin sulfate, pectin, starch and amylose, dextran, chitosan, inulin. Basics of colon-specific targeting, formulation aspects, microflora influence and application of cross-linking techniques and polymer mixtures for targeting drugs into the colon are presented. Adventages and disadventages of colon-specific drug delivery are also described. A number of polymers is important in the context of colon-specific drug delivery. Considerable progress has been made over last three decades in this area. Although extensive investigations have to be done in the area of microflora endogenous ecosystems and enzymatic science, immunoactivity of biopolymers, and absorption enhancers for colonic mucous. Completely synthetic polymers of good swelling properties and sensitive to bacterial enzymes are also possible in the close future.     

Biodegradable polyphosphazenes for drug delivery applications

Biodegradable polymers such as poly(alpha-hydroxy acids), poly(anhydrides), poly(ortho esters), poly(amino acids) and polyphosphazenes have raised considerable interest as short-term medical implants due to their transient nature. Among these, polyphosphazenes are a relatively new class of polymers, quite distinct from all the biodegradable polymers synthesized so far, due to their synthetic flexibility and versatile adaptability for applications. These are high molecular weight, essentially linear polymers with an inorganic backbone of alternating phosphorous and nitrogen atoms bearing two side groups attached to each phosphorous atom. Controlled tuning of physico-chemical properties, including biodegradability, can be achieved in this class of polymers via macromolecular substitutions. Biodegradable polyphosphazenes, due to their hydrolytic instability, nontoxic degradation products, ease of fabrication and matrix permeability, are an excellent platform for controlled drug delivery applications. This review discusses the mode of degradation and drug delivery applications of biodegradable polyphosphazenes.     

Biodegradable microspheres for prolidase delivery to human cultured fibroblasts

Prolidase deficiency (PD) is a rare autosomal recessive disorder caused by inadequate levels of the cytosolic exopeptidase prolidase (E.C. 3.4.13.9), for which there is not, as yet, a resolutive cure. We have investigated whether biodegradable microspheres loaded with prolidase could release active enzyme inside cells, to consider this system as a possible therapeutic approach for prolidase deficiency. Poly(lactide-co-glycolide) microspheres were prepared, modifying the classical double emulsion solvent evaporation method to mitigate the burst effect of the enzyme from the microspheres. Ex-vivo experiments were performed, by incubating microencapsulated prolidase with cultured fibroblasts from PD patients and from controls, to determine the amount of active enzyme delivered to the cells. The microparticulate drug delivery system described carried small amounts of active prolidase inside fibroblasts, ensuring a response to the intracellular accumulation of X-Pro dipeptides, the mechanism that is supposed to be responsible for the development of clinical manifestations of this disorder in man. A positive result of the presence of active enzyme inside cells was an improvement in fibroblast shape.     

Mucoadhesive microspheres for controlled drug delivery

Mucoadhesion is a topic of current interest in the design of drug delivery systems. Mucoadhesive micro-spheres exhibit a prolonged residence time at the site of application or absorption and facilitate an intimate contact with the underlying absorption surface and thus contribute to improved and/or better therapeutic performance of drugs. In recent years such mucoadhesive microspheres have been developed for oral, buccal, nasal, ocular, rectal and vaginal routes for either systemic or local effects. The objective of this article is review the principles underlying the development and evaluation of mucoadhesive microspheres and the research work carried out on these systems.     

Biodegradable thermosensitive copolymer hydrogels for drug delivery

Biodegradable thermogelling copolymer hydrogels have great applicative potential in areas such as sustained drug release, gene delivery and tissue engineering. These injectable materials can be implanted in the human body with minimal surgical intervention. The thermosensitive copolymers have been incorporated with a variety of biocompatible and biodegradable components such as poly(D,L-lactic acid-co-glycolic acid), poly(L-lactic acid), poly (L-carprolactone), poly([R]-3-hydroxybutyrate), poly(organophosphazene), poly(peptide), poly(propylene fumarate), poly(propylene phosphate), polyacetal and poly(ortho ester). Various formulations consisting of the copolymers and therapeutic agents have been developed and the sustained release of these agents has been demonstrated. This review aims to provide a comprehensive summary of the recent developments in this field of study and highlights the most recent intellectual property and research papers.     

Biodegradable polymeric nanocarriers for pulmonary drug delivery

BACKGROUND: Pulmonary drug delivery is attractive for both local and systemic drug delivery as a non-invasive route that provides a large surface area, thin epithelial barrier, high blood flow and the avoidance of first-pass metabolism. OBJECTIVE: Nanoparticles can be designed to have several advantages for controlled and targeted drug delivery, including controlled deposition, sustained release, reduced dosing frequency, as well as an appropriate size for avoiding alveolar macrophage clearance or promoting transepithelial transport. METHODS: This review focuses on the development and application of biodegradable polymers to nanocarrier-based strategies for the delivery of drugs, peptides, proteins, genes, siRNA and vaccines by the pulmonary route. RESULTS/CONCLUSION: The selection of natural or synthetic materials is important in designing particles or nanoparticle clusters with the desired characteristics, such as biocompatibility, size, charge, drug release and polymer degradation rate.     

Biodegradable polymeric drug delivery systems

The use of biodegradable polymeric materials as drug carriers is a relatively new dimension in polymeric drug delivery systems. A number of biodegradable or bioerodible polymers, such as poly (lactic/glycolic acid) copolymer, poly(α-amino acid), polyanhydride, and poly (ortho ester) are currently being investigated for this purpose. These polymers are useful for matrix and reservoir-type delivery devices. In addition, when chemical functional groups are introduced to the biodegradable polymer backbone, such as poly (N-(2-hydroxypropy) methacrylamide), the therapeutic agent can be covalently bound directly orvia spacer to the backbone polymer. These polymer/drug conjugates represent another new dimension in biodegradable polymeric drug delivery systems. In this paper, major emphasis is placed on clinical applications of biodegradable polymeric delivery systems. In addition, examples of biodegradable polymeric durg delivery systems currently being investigated will be discussed for the purpose of demonstrating the potential importance of this new field.     

Trehalose-hydroxyethylcellulose microspheres containing vancomycin for topical drug delivery.

A new formulation, in which vancomycin is entrapped into trehalose and hydroxyethylcellulose (Natrosol) spherical matrices, is described. Microspheres were produced by the solvent evaporation method. The entrapped drug was fully recovered following microspheres dissolution. Differential scanning calorimetry analyses proved that Natrosol maintains trehalose in its amorphous form. The stabilizing effects of trehalose on vancomycin were evaluated even after long storage and heating of microspheres. Calorimetric data indicated no decomposition of the entrapped drug. In vitro drug release, already performed by using a general two-compartment linear time-invariant open model, suggests that the new delivery system is suitable for topical application on extensive and purulent or burn wounds, when the skin is heavily damaged and the barrier disrupted. The system activation is determined by osmotic phenomena. The prepared new delivery system seems to have characteristics suitable for topical applications on extensive and purulent wounds. The system is able to take away serous exudates from wounds, thus letting the matrix to swell and form a viscous gel-like dispersion that, in turn, enables drug diffusion.     

Biodegradable elastomers in drug delivery

BACKGROUND: Biodegradable elastomers have been used in many different manners for controlled drug delivery. The development of new biodegradable elastomers has recently increased, driven mainly by tissue engineering research. OBJECTIVE: This review outlines the different uses of biodegradable elastomers in controlled release. METHODS: This review was limited to those papers wherein the polymer chosen as the delivery vehicle was demonstrably elastomeric. CONCLUSION: Biodegradable elastomers have an established role in controlled release and an expanding role in combination scaffolds providing controlled release and mechanical stimulation capability for tissue regeneration/engineering.     

Microdialysis assessment of drug delivery systems for vitreoretinal targets

Posterior segment drug delivery challenges inherent in the treatment of many sight-threatening diseases have become increasingly apparent. Therapeutic interventions for ocular diseases such as neovascular retinopathies, inflammatory and/or infectious diseases may involve drug delivery to vitreoretinal targets. An important part of successful therapeutic strategies for such diseases involves verification that efficacious concentrations of the pharmacological agent are achieved within relevant intraocular regions. Microdialysis has been effectively employed for characterizing intraocular disposition in both anterior and posterior segments, providing important documentation of successful drug delivery to desired targets. Recent papers that showcase the maturation in the model development of microdialysis approaches for estimating posterior segment pharmacokinetics and further validation of the methodology are described in this review. Special problems examined include anterior and posterior ocular clearance mechanisms, intraocular metabolism and active transport of drugs.     

Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate

Liver parasite burdens of Leishmania donovani in the mouse have been determined after treatment with intravenous administration of sodium stibogluconate in the free or carrier form. The carrier form, in which the drug was covalently bound to polyacryl starch microparticles, was up to 100x more effective than the free form in this murine model of visceral leishmaniasis. Empty microparticles had no effect on liver parasite burdens and the enhanced in-vivo antileishmanial activity of the carrier form of the drug was apparently due to passive drug delivery to the infected liver.     

Silicone microspheres for pH-controlled gastrointestinal drug delivery

Silicone microspheres containing pH-sensitive hydrogels are prepared, characterized and evaluated for their potential pH-controlled gastrointestinal (GI) drug delivery. The pH-sensitive hydrogels are semi-interpenetrating polymer networks (semi-IPN(s)) made of varying proportions of poly(methacrylic acid-co-methylmethacrylate) (Eudragit (EUD) L100 or EUD S100) and crosslinked polyethylene glycol 8000 (P8000C). Up to 35 wt% hydrogel particles of mean volume diameters from 89 to 123 microm, medicated with 15 wt% prednisolone (PDN), are encapsulated, with 100% efficiency, into morphologically acceptable silicone microspheres in the 500-1000 microm size range, by a modified emulsion vulcanization method. Microspheres are eluted for 9 h with isotonic fluids at pH values increasing from 1.2 to 7.4, to simulate transit across the GI regions. PDN release depends on dissolution medium pH and on hydrogel composition, which determines hydrogel pH-sensitivity. With the P8000C-EUD L100 (1:2) semi-IPN, the release shows a marked peak at pH 6.8. The P8000C-EUD S100 (1:2) semi-IPN causes a gastroprotection and an almost uniform distribution of released drug between media at pH 6.8 and 7.4. With the P8000C-EUD S100 (1:1) semi-IPN, the dose fraction released to gastric fluid increases to match the values for the media at pH 6.8 and 7.4. With the pH-insensitive, highly swelling, P8000C, the largest dose fraction is released to the gastric medium and release is of Fickian type. With semi-IPNs, release depends weakly on the buffer molarity of the dissolution medium, a reduction from 0.13 to 0.032 of which renders the release rate to the media at pH 6.8 and 7. 4 more uniform.Copyright     

Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery

Drug delivery to ocular region is a challenging task. Only 1–2% of drug is available in eye for therapeutic action, rest of the drug is drained out through nasolachrymal drainage system and other ocular physiological barriers. To overcome these problems of conventional dosage form, novel drug delivery systems are explored like nanoparticles. In our present work, levofloxacin encapsulated poly(lactic-co-glycolic acid) nanoparticles were developed and evaluated for various parameters like particle size, ζ potential, in vitro drug release and ex vivo transcorneal permeation. Microbiological efficacy was tested against Staphylococcus aureus using cup-plate method. Precorneal residence time was studied on albino rabbits by γ scintigraphy after radiolabeling of levofloxacin by Tc-99m. Ocular tolerance was evaluated using hen’s egg chorioallantoic membrane (HET-CAM) test. The developed nanoparticles were of spherical shape with a mean particle size of 190–195?nm with a ζ potential of ?25 mV. The drug entrapment efficiency was found to be near 85%. In vitro drug release profile shows initial burst release followed by extended release up to 24?h. Microbiological assay showed equivalent zone of inhibition compared to marketed formulation. γ Scintigraphy images of developed formulation, suggested a good spread and good retention over precorneal area. The nanosuspension thus developed was retained for the longer time and drained out from the eye very slowly compared to marketed formulation as significant radioactivity was recorded in later in kidney and bladder. The developed nanosuspension with a mean score of 0.33 up to 24?h in HET-CAM assay, showed the nonirritant efficacy of developed formulation. The stability studies yielded a degradation constant less then 5?×?10^?4, proving a stable formulation with an arbitrary shelf life of 2 years.     

Biodegradable polymers in controlled drug delivery

Erosion mechanisms are divided into three types and drug release within each type is described. Type I erosion involves hydrolysis of hydrogels and these are useful in the controlled release of macromolecules entangled within their network structure. Type II erosion involves solubilization of water-insoluble polymers by reactions involving groups pendant from the polymer backbone. Of particular interest are polymers that solubilize by ionization of carboxylic acid groups, and the utilization of those systems is described. Type III erosion involves cleavage of hydrolytically labile bonds within the polymer backbone and four distinct polymer systems within this category are under development. One system involves the diffusion of drugs from a reservoir through a bioerodible membrane, another system utilizes microcapsules, a third system utilizes monolithic devices, and the fourth system utilizes drugs chemically bound to a bioerodible polymer.     

Albumin microspheres. II: Applications in drug delivery

Albumin microspheres are colloidal particles which are known to sustain the release of entrapped therapeutic agent(s). The rate at which these particles metabolise in vivo can be manoeuvred by varying their synthetic conditions. These particles alter the in vivo distribution of included drugs and hence this carrier has been extensively investigated for drug delivery and targeting in laboratory animals. Attempts have also been made to use this carrier for the delivery of anti-cancer agents in patients with liver cancer. This review is focused on the experimental and clinical applications of albumin microspheres in drug delivery. An account of the toxicological properties of these particles is also presented.     

凝集素修饰透黏膜微粒给药系统

通过对近年来相关文献的检索,本文介绍了凝集素修饰的微球、纳米粒和脂质体,以及凝集素对不同微粒系统的修饰机制,综述凝集素修饰微粒给药系统在透黏膜给药中的应用,认为凝集素修饰微粒给药系统有较好的应用前景。     

Biodegradable films developed by electrospray deposition for sustained drug delivery

The objective of present study is to develop biodegradable films with controllable thickness for sustained release applications using a combination of electrospray deposition techniques. The model anticancer drug-paclitaxel is encapsulated inside PLGA films. The morphology observed by atomic force microscopy and scanning electron microscopy reveals that the film has a flat surface together with a dense structure. X-ray photo-electron spectroscopy results show that some amount of paclitaxel is found on the surface layer of films. X-ray diffractometry (XRD) analysis suggests that paclitaxel is in an amorphous form in the polymer matrix even for up to 30% drug loading. Differential scanning calorimetry (DSC) study further proved that paclitaxel is in a solid solution state in polymer films. In vitro release profile indicates that sustained release of paclitaxel from the films is for more than 85 days, without the tri-phasic release profile typically for PLGA films. The phase contrast images clearly suggests a slight decrease in the number of C6 glioma cells as the paclitaxel loading within the polymeric films is increased. The results of MTT assay employed to quantify the cell viability correlates well with the observation from phase contrast microscopy.